Mind Medicine (MindMed) Inc.
NasdaqGS:MNMD Rapporto sulle azioni
Cap. di mercato: US$622.6m
Mind Medicine (MindMed) Salute del bilancio
Salute finanziaria criteri di controllo 5/6 Mind Medicine (MindMed) ha un patrimonio netto totale di $262.2M e un debito totale di $24.3M, che porta il suo rapporto debito/patrimonio netto a 9.3%. Le sue attività totali e le sue passività totali sono rispettivamente $319.8M e $57.6M.
Informazioni chiave
9.3%
Rapporto debito/patrimonio netto
Indice di copertura degli interessi n/a Contanti US$295.28m Patrimonio netto US$262.19m Totale passività US$57.58m Totale attività US$319.77m
Aggiornamenti recenti sulla salute finanziaria
Mostra tutti gli aggiornamenti
Mind Medicine: Two Pathways Created From One Pipeline Clinical Candidate Nov 04
CEO & Director notifies of intention to sell stock Sep 27
Price target increased by 9.3% to US$26.50 Aug 29
Executive President exercised options and sold US$81k worth of stock Aug 25
Mind Medicine (Mindmed) Inc. Presents Phase 2B Study of Mm120 for Generalized Anxiety Disorder (Gad) At American Psychiatric Association Aug 22
Psychedelic Stocks: Focus On Their Cash Aug 15 Mind Medicine (MindMed) Inc. has completed a Follow-on Equity Offering in the amount of $74.998573 million. Aug 10
Mind Medicine (MindMed) Inc. has filed a Follow-on Equity Offering. Aug 09
Mind Medicine (MindMed) Inc. to Report Q2, 2024 Results on Aug 13, 2024 Aug 06
Mindmed Appoints Stephanie Fagan as Chief Corporate Affairs Officer Jul 29
Mind Medicine (MindMed) Inc. Announces Issuance of New Patent for MM120 Orally Disintegrating Tablet (ODT) Jul 17
Mind Medicine (MindMed) Inc.(NasdaqGS:MNMD) dropped from Russell 3000E Value Index Jul 03
Mind Medicine (MindMed) Inc Announces Constructive End-of-Phase 2 Meeting with U.S. FDA for MM120 in Generalized Anxiety Disorder (GAD) Jun 21
MindMed: Despite MDMA Setback, Still Hope In Light Of Differentiating Factors Jun 05
Mind Medicine (MindMed) Inc., Annual General Meeting, Jun 10, 2024 Apr 28
Mind Medicine: GAD Program Success Continues With BTD And Positive Treatment Data Apr 04
Numinus Wellness Congratulates Mindmed on Positive Results from Phase 2B Clinical Trials of Mm120 for Generalized Anxiety Disorder Mar 09
New major risk - Shareholder dilution Mar 09 Mind Medicine (MindMed) Inc. has completed a Follow-on Equity Offering in the amount of $100.000002 million. Mar 08
Price target increased by 10% to US$28.67 Mar 08 Mind Medicine (MindMed) Inc. announced that it expects to receive $75 million in funding from Deep Track Capital, LP, Commodore Capital Mar 08
Mind Medicine (MindMed) Inc. has completed a Follow-on Equity Offering in the amount of $100.000002 million.
Price target increased by 7.5% to US$26.17 Feb 28
Mind Medicine: Positive MM-120 Data Leads To Other 2024 Catalysts Feb 02
Mind Medicine (Mindmed) Inc. Provides Anticipated Production Milestones for 2024 Jan 09
Mind Medicine Announces Positive Topline Results from Phase 2b Trial of MM-120 in Generalized Anxiety Disorder Dec 15
New minor risk - Share price stability Nov 30
Price target increased by 14% to US$25.83 Nov 17
Price target decreased by 36% to US$14.50 Nov 07
New major risk - Revenue and earnings growth Nov 03
Price target increased by 14% to US$25.83 Nov 03
New minor risk - Market cap size Oct 28
Mind Medicine (MindMed) Inc. Completes Enrollment of Phase 2A Trial of Mm-120 in Adults with Attention-Deficit/Hyperactivity Disorder (ADHD) Oct 25
Mind Medicine Completes Enrollment and Dosing in Study Mmed008 Sep 14
Chief Financial Officer recently sold US$76k worth of stock Aug 31
New minor risk - Share price stability Aug 05
Mind Medicine (Mindmed) Inc. Elects David Gryska to the Board of Directors Jun 22
FCM MM Holdings Posts Material on Social Media Platforms Jun 17
FCM MM Holdings Calls for Socially Responsible Investors to Vote for Change at Mind Medicine Jun 13 FCM MM Holdings Posts Material on Twitter
FCM MM Holdings Provides Information to Shareholders of Mind Medicine Jun 09
FCM MM Holdings Condemns the Report Issued by Institutional Shareholder Services Jun 07
FCM MM Holdings LLC Issues a Letter to the Shareholders of Mind Medicine Inc Jun 04
FCM MM Holdings Posts Materials to Reddit Jun 03
FCM MM Holdings Sends Letter to Shareholders of Mind Medicine (MindMed) Jun 02
Mind Medicine Posts Materials to Twitter Jun 01 FCM MM Holdings Issues an Investor Presentation to Shareholders of Mind Medicine
Mind Medicine (MindMed) (NASDAQ:MNMD) Is In A Good Position To Deliver On Growth Plans May 23
Mind Medicine (MindMed) Inc. Enters into Phase 2b Clinical Trial Evaluating MM-120 (lysergide D-Tartrate) for GAD May 18
FCM Director Nominees Will Put MindMed Drug Development Process Back on Track May 16
Mind Medicine Launches a Website and Post the Materials May 05
Mind Medicine (MindMed) Inc., Annual General Meeting, Jun 15, 2023 May 04
We're Hopeful That Mind Medicine (MindMed) (NASDAQ:MNMD) Will Use Its Cash Wisely Feb 07
Price target decreased by 11% to US$27.63 Feb 03
High number of new and inexperienced directors Feb 03
FCM MM Holdings LLC Sends a Letter to Mind Medicine (MindMed) Inc Nov 15 FCM MM HOLDINGS, LLC Demands Federal Investigation to Probe Serious Allegations of Misconduct at Mind Medicine (MindMed) Inc
MindMed: Not The Horse To Back If You're Looking To Buy Psychedelics Oct 19
Mind Medicine Announces Initiation of Phase 1 Comparative PK/PD Trial of R-, S- and Racemic MDMA Oct 06
FCM MM HOLDINGS Sends Letter to the Board of Mind Medicine Sep 30
MindMed announces proposed public offering of common shares Sep 27
Mind Medicine (MindMed) Inc. Collaborators Dose First Patient in Phase 1 Investigator-Initiated Trial of MDMA-Like Substances Sep 21
Price target decreased to US$51.10 Sep 20
MindMed doses first patient in phase 1 trial examining psychedelic MDMA-like substances Sep 20
Mind Medicine Regains Compliance with Nasdaq's Minimum Bid Price Listing Requirement Sep 15
MindMed regains compliance with Nasdaq's minimum bid price listing requirement Sep 14
Mind Medicine (MindMed) Inc. Announces Positive Results from Collaborators' Placebo-Controlled Investigator-Initiated Trial Published in Peer-Reviewed Journal Sep 09
MindMed: Confusing MEME Rally Hides A Company That Looks Empty Of Value Sep 04
Mind Medicine (MindMed) Inc. Announces First Patient Dosed in Phase 2b Trial of MM-120 in Generalized Anxiety Disorder Aug 26
Mind Medicine (MindMed) (NASDAQ:MNMD) Is In A Good Position To Deliver On Growth Plans Aug 26
Magic mushrooms psychedelic compound can help with treatment of alcohol use disorder Aug 24
MindMed soars 71% as it appears to be following in Bed Bath & Beyond's footsteps Aug 18 Mind Medicine (MindMed) Inc. Announces Board Appointments
Mind Medicine GAAP EPS of -$0.04 beats by $0.01 Aug 11
Mind Medicine announces 1-for-15 reverse stock split Aug 04
MindMed: Another Psychedelic Medicine Play Trading At A Potential Discount Jul 12
Analisi della posizione finanziaria
Passività a breve termine: Le attività a breve termine ( $299.4M ) di MNMD superano le sue passività a breve termine ( $33.3M ).
Passività a lungo termine: Le attività a breve termine di MNMD ( $299.4M ) superano le sue passività a lungo termine ( $24.3M ).
Storia e analisi del rapporto debito/patrimonio netto
Livello di debito: MNMD ha più liquidità del suo debito totale.
Riduzione del debito: Dati insufficienti per determinare se il rapporto debito/patrimonio netto di MNMD si sia ridotto negli ultimi 5 anni.
Analisi della pista di contanti Per le società che in passato sono state mediamente in perdita, valutiamo se hanno almeno un anno di liquidità.
Pista di liquidità stabile: MNMD ha una cash runway sufficiente per più di 3 anni in base al suo attuale free cash flow .
Previsione Cash Runway: MNMD ha una liquidità sufficiente per 2.6 anni se il flusso di cassa libero continua a ridursi ai tassi storici del 27.5 % ogni anno.
Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"display-ssr-flag","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}
